Celldex to Participate in Upcoming November Investor Conferences
November 10, 2022 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following investor conferences in...
Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 09, 2022 16:01 ET
|
Celldex Therapeutics, Inc.
- Multiple clinical-stage programs on track for data updates in upcoming months - HAMPTON, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial...
Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 08, 2022 16:01 ET
|
Celldex Therapeutics, Inc.
- Positive interim data from barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria presented at EAACI 2022 - - First patients dosed in Phase 2 chronic urticaria studies - HAMPTON, N.J., Aug....
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
July 21, 2022 08:00 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., July 21, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the...
Celldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022
June 30, 2022 18:01 ET
|
Celldex Therapeutics, Inc.
-Rapid, profound and durable responses across multiple dosing groups with favorable safety profile--Mean reduction from baseline in urticaria activity (UAS7) of 66.6% in 1.5 mg/kg dose group at week...
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
June 21, 2022 08:00 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the...
Celldex Announces Two New Appointments to its Board of Directors
June 16, 2022 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Cheryl L. Cohen and Dr. Garry Neil to the company’s Board of...
Celldex to Present at the 2022 Jefferies Global Healthcare Conference
June 06, 2022 16:05 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the 2022 Jefferies Global...
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022
May 19, 2022 09:23 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab (CDX-0159) in patients with...
Celldex Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 05, 2022 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. ...